Not many biotech/pharmaceutical companies are valued by their cash backing,especially when they have two proprietary drugs and 5 generic.Their intention of focussing on the Asian market is a good move;the US market is pretty much a closed shop to outsiders.Being based in Asia will help them penetrate the markets and they can also be a distributor of other generic products.Sonic has done most of the work for them virtually at no cost.
